Analysts’ Recent Ratings Updates for Exelixis (EXEL)

A number of research firms have changed their ratings and price targets for Exelixis (NASDAQ: EXEL):

• 5/19/2026 – Exelixis had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 5/9/2026 – Exelixis was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/7/2026 – Exelixis had its price target raised by HC Wainwright from $54.00 to $56.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Exelixis had its price target raised by TD Cowen from $51.00 to $55.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Exelixis had its price target raised by Morgan Stanley from $49.00 to $50.00. They now have an “equal weight” rating on the stock.
• 5/6/2026 – Exelixis had its price target raised by Stifel Nicolaus from $44.00 to $47.00. They now have a “hold” rating on the stock.
• 5/6/2026 – Exelixis had its price target raised by Wells Fargo & Company from $35.00 to $40.00. They now have an “equal weight” rating on the stock.
• 4/27/2026 – Exelixis was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/20/2026 – Exelixis had its price target raised by Barclays PLC from $44.00 to $45.00. They now have an “equal weight” rating on the stock.
• 4/18/2026 – Exelixis was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 3/25/2026 – Exelixis was upgraded by Truist Financial Corporation to “strong-buy”.

Insider Activity at Exelixis

In related news, CFO Christopher J. Senner sold 34,901 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the completion of the transaction, the chief financial officer directly owned 952,317 shares in the company, valued at approximately $47,615,850. The trade was a 3.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mary C. Beckerle sold 7,712 shares of Exelixis stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $48.45, for a total transaction of $373,646.40. Following the transaction, the director directly owned 17,524 shares in the company, valued at $849,037.80. This represents a 30.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 177,790 shares of company stock worth $8,275,453 in the last quarter. 2.60% of the stock is currently owned by insiders.

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.